The pharmaceutical side of psychedelics

Following strict scientific standards to protect patients and help produce reliable clinical trials results

Sponsored
Discussion Forum: Biomind Labs Inc
List Message View
Thread Message View
New Message
Message Title
Rating
Author / Date
Icon agoracom END OF DAY ALERT: Biomind Labs (BMND: NEO) (BMNDF: OTC) Up 12% On 3K Shares

AGORACOM-AM
Sep 09, 2022 04:20PM
Icon agoracom END OF DAY ALERT: Biomind Labs (BMND: NEO) (BMNDF: OTC) Up 10% On 4K SHARES

AGORACOM-AM
Sep 02, 2022 04:20PM
Icon agoracom END OF DAY ALERT: Biomind Labs (BMND: NEO) (BMNDF: OTC) Up 11% On 4K SHARES

AGORACOM-AM
Aug 23, 2022 04:20PM
Icon agoracom Biomind Labs Appoints Former FDA Director Dr. Thomas Laughren as Medical Advisor for Clinical Trials

AGORACOM
Jul 27, 2022 07:25AM
Icon agoracom Biomind Labs Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08 Candidate…

AGORACOM-AM
May 26, 2022 07:25AM
Icon agoracom Biomind Labs to Argument Which Psychedelic Medicines Will Lead the Industry Into Its Next Phase of Evolution at The National Gallery in London

AGORACOM-AM
May 09, 2022 07:20AM
Icon agoracom Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based...

AGORACOM-AM
Apr 26, 2022 08:38AM
Icon agoracom Biomind Labs to Participate in the PSYCH Symposium at the National Gallery in London

AGORACOM-AM
Apr 12, 2022 07:25AM
Icon agoracom Biomind Labs to Present at Benzinga Psychedelics Capital Conference in the U.S. on April 19th 2022

AGORACOM-AM
Mar 30, 2022 08:37AM
Icon agoracom Biomind Labs to Commence Commercial Clinical Trial on Its Proprietary Mescaline Candidate BMND06

AGORACOM-AM
Mar 24, 2022 08:10AM
Icon agoracom Biomind Labs Opens a New Clinical Psychedelic Research Facility

AGORACOM-AM
Mar 17, 2022 07:25AM
Icon agoracom Biomind Labs Receives Approval for a Second Phase II Clinical Trial for Treatment-resistant Depression

AGORACOM-AM
Mar 09, 2022 07:25AM
Icon agoracom Biomind Labs Announces Positive Results on in vivo Studies for Its Proprietary Drug Candidate BMND07

AGORACOM-AM
Mar 03, 2022 07:30AM
Icon agoracom Biomind Labs Announces DTC Eligibility in the United States

AGORACOM-AM
Feb 24, 2022 08:12AM
Icon agoracom Biomind Labs Announces Upgrade to the OTCQB® Venture Market in the United States

AGORACOM-AM
Feb 17, 2022 07:30AM
Icon agoracom Biomind Labs to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021

AGORACOM-AM
Dec 02, 2021 07:45AM
Icon agoracom Biomind Labs Completes Development of a Thermosensitive Nasal Gel Pharmaceutical Dosage Form

AGORACOM-AM
Nov 18, 2021 07:45AM
Icon agoracom Biomind Labs to Present at H.C. Wainwright 2nd Annual Psychedelics Conference

AGORACOM-AM
Nov 11, 2021 08:00AM
Icon agoracom AGORACOM Small Cap 60: Biomind Is Developing a Combination of Dose, Route of Administration and Indication

AGORACOM
Sep 14, 2021 04:46PM
Icon agoracom VIDEO – Biomind Labs (BMND: NEO) Is Developing The Next Generation of Medicines For The 21st Century – The Pharmaceutical Side of Psychedelics

AGORACOM
Aug 25, 2021 04:42PM
New Message